TRIETHYLENE MELAMINE IN THE TREATMENT OF LYMPHOMAS AND OTHER NEOPLASTIC DISEASES
Authors: O W BURTNER, L C JENSEN, J M RUMBALL
Journal: Annals of Internal Medicine (1953)

Article1 June 1953TRIETHYLENE MELAMINE IN THE TREATMENT OF LYMPHOMAS AND OTHER NEOPLASTIC DISEASESO. WHITMORE BURTNER, M.D., LOUIS C. JENSEN, M.D., JOHN M. RUMBALL, M.D., F.A.C.P.O. WHITMORE BURTNER, M.D.Search for more papers by this author, LOUIS C. JENSEN, M.D.Search for more papers by this author, JOHN M. RUMBALL, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-38-6-1222 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe usefulness of nitrogen mustard (HN2) in the palliative treatment of certain lymphomas has become well established since the original trials in 1942.1 More recently, a nitrogen mustard-like preparation, triethylene melamine (TEM) has been found to have therapeutic effects somewhat similar to those of nitrogen mustard itself. This new compound possesses the practical advantages, as contrasted with nitrogen mustard, of being effective by mouth, producing less nausea and little or no vomiting, obviating the necessity of hospitalization during treatment and providing a compound with prolonged effect well suited to spaced maintenance therapy.The structural formula of triethylene melamine, chemically 2,...Bibliography1. Karnofsky DA: Nitrogen mustards in the treatment of neoplastic disease, in Dock, W., and Snapper, I.: Advances in internal medicine, vol. 4, 1950, Year Book Publishers, Chicago, p. 1. Google Scholar2. KarnofskyBurchenalArmisteadSouthamBernsteinCraverRhoads DAJHGCCMJLLFCP: Triethylene melamine in the treatment of neoplastic disease; a compound with nitrogen mustard-like activity suitable for oral and intravenous use, Arch. Int. Med. 87: 477-516 (April) 1951. CrossrefGoogle Scholar3. LewisCrossley MRML: Retardation of tumor growth in mice by oral administration of ethylenimine derivatives, Arch. Biochem. 26: 319 (April) 1950. MedlineGoogle Scholar4. BurchenalCrossleyStockRhoads JHMLCCCP: The action of certain ethylenimine (Aziridine) derivatives on mouse leukemia, Arch. Biochem. 26: 321 (April) 1950. MedlineGoogle Scholar5. RhoadsKarnofskyBurchenalCraver CPDAJHLF: Triethylene melamine in the treatment of Hodgkin's disease and allied neoplasms, Tr. A. Am. Physicians 63: 136, 1950. MedlineGoogle Scholar6. Rottino A: Triethylene melamine in treatment of Hodgkin's disease and related disorders, New York State J. Med. 52: 346 (Feb. 1) 1952. MedlineGoogle Scholar7. SilverbergDameshek JHW: Use of triethylene melamine in treatment of leukemia and leukosarcoma, J. A. M. A. 148: 1015-1021 (Mar. 22) 1952. CrossrefMedlineGoogle Scholar8. WrightPrigotWrightArons JCALTI: Further observations on the use of triethylene melamine in neoplastic diseases, Arch. Int. Med. 89: 387-404 (March) 1952. CrossrefGoogle Scholar9. RundlesBarton RWWB: Triethylene melamine in the treatment of neoplastic disease, Blood 7: 483-508 (May) 1952. CrossrefMedlineGoogle Scholar10. KravitzDiamondCraver SCHDLF: The clinical use of triethylene melamine, Blood 7: 729-742 (July) 1952. CrossrefMedlineGoogle Scholar11. KravitzDiamondCraver SCHDLF: Uremia complicating leukemia chemotherapy; report of a case treated with triethylene melamine, J. A. M. A. 146: 17 (Aug. 25) 1951. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication November 18, 1952.Read before the southeastern regional meeting of the American College of Physicians, Havana, Cuba, November 7, 1952.A preliminary report of 17 of the 38 cases in this series was read before the annual meeting of the Southern Section of the American Federation for Clinical Research, New Orleans, January 26, 1951.Triethylene melamine was furnished through the courtesy of Dr. John Ruegsegger, Medical Director, Lederle Laboratories Division, American Cyanamid Company, Pearl River, New York. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byReactivity of Aziridine-2-Carboxamide (Leakadine) with Nucleophiles in Aqueous Solutions*Die LymphogranulomatoseEfficacy of cyclophosphamide in the management of reticulum cell sarcomaSUMMARY OF RESULTS OBTAINED WITH TEMCytologie und Klinik der LymphogranulomatoseComparative Therapeutic Activity of the Nitrogen Mustards and Allied CompoundsTherapy of the malignant lymphomasOral triethylene melamine therapy in human neoplastic diseasePRIMARY CARCINOMA OF THE LIVER: REPORT OF 20 CASES, INCLUDING TWO TREATED WITH TRIETHYLENE MELAMINE*HENRY M. WILSON, M.D.Triethylene Melamine in the Treatment of Lymphomas and Leukemias 1 June 1953Volume 38, Issue 6Page: 1222-1244KeywordsHospitalizationsLymphomaMouthNauseaPalliative careRiversVomiting ePublished: 1 December 2008 Issue Published: 1 June 1953 PDF downloadLoading ...